Dusseldorf - Delayed Quote • EUR LAVA Therapeutics NV (4PKB.DU) Follow Compare 1.0200 -0.0100 (-0.97%) As of 9:10:19 AM GMT+1. Market Open. Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for 4PKB.DU 1D 5D 7.37% 1M -33.77% 3M -29.17% 6M -37.42% YTD 7.37% 1Y -35.44% 5Y -91.59% All -91.59% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: 4PKB.DU View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027 LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference LAVA Reports Second Quarter 2024 Financial Results and Business Update LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference LAVA Announces Annual Meeting of Shareholders LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference LAVA Therapeutics Full Year 2023 Earnings: Revenues Disappoint LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)